Andrew Gengos's Net Worth
-$242 Thousand
Who is Andrew Gengos?
Andrew Gengos does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include Cyteir Therapeutics, Inc., SYNLOGIC, INC., ImmunoCellular Therapeutics, Ltd., and Athira Pharma, Inc..
SEC CIK
Andrew Gengos's CIK is 0001563623
Past Insider Trading and Trends
2023 was Andrew Gengos's most active year for acquiring shares with 12 total transactions. Andrew Gengos's most active month to acquire stocks was the month of May. 2024 was Andrew Gengos's most active year for disposing of shares, totalling 2 transactions. Andrew Gengos's most active month to dispose stocks was the month of December. 2023 saw Andrew Gengos paying a total of $243,017.22 for 485,012 shares, this is the most they've acquired in one year. In 2016 Andrew Gengos cashed out on 3,284 shares for a total of $6,732.20, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Cyteir Therapeutics, Inc. (CYT) No price found
Chief Business Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 22
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
SYNLOGIC, INC. (SYBX) Snapshot price: $1.58
Chief Operating Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 31
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
ImmunoCellular Therapeutics, Ltd. (IMUC) Snapshot price: $0.0182
President and CEO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -38.49% | -3.28K |
$2.05 | -$6,732.20 | 5.25K |
Dec 31
| |||
Form 4
| +78.40% | 150K |
—
|
—
| 341.33K |
Mar 11
| |||
Form 4
| +27.03% | 10K |
$0.44 | $4,350.00 | 47K |
Nov 30
| |||
Form 4/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
| +191.49% | 150K |
—
|
—
| 228.33K |
Mar 20
| |||
Form 4
| +111.71% | 41.33K |
$0.60 | $24,799.80 | 78.33K |
Feb 18
| |||
Form 4
| +37.04% | 10K |
$0.90 | $8,994.00 | 37K |
Aug 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 7
| |||
Form 4
|
∞
| 27K |
$0.72 | $19,361.70 | 27K |
Dec 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Athira Pharma, Inc. (ATHA) Snapshot price: $0.5407
CFO and Chief Business Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| +16.38% | 13.73K |
$0.96 | $12,680.05 | 97.53K |
May 20 - Sep 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 14
| |||
Form 4/A
| +4.74% | 3.79K |
$2.91 | -$3,515.28 | 83.8K |
Jan 4 - Jan 5
| |||
Form 4
| +4.74% | 3.79K |
$2.91 | -$3,515.28 | 83.8K |
Jan 4 - Jan 5
| |||
Form 4
| +23.07% | 15K |
$3.43 | $51,445.01 | 80.01K |
Jun 7
| |||
Form 4
|
∞
| 65.01K |
$2.95 | $191,572.21 | 65.01K |
Jun 2 - Jun 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 18
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |